Manufacturer of Controlled Substances; Notice of Application, 23950 [E6-6117]

Download as PDF 23950 Federal Register / Vol. 71, No. 79 / Tuesday, April 25, 2006 / Notices Schedule Drug Concentrate (9670). of Poppy Straw DEPARTMENT OF JUSTICE II Drug Enforcement Administration The company plans to import the listed controlled substances to manufacture other controlled substances. Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than May 25, 2006. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substance listed in Schedule I or II are, and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied. Dated: April 18, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–6116 Filed 4–24–06; 8:45 am] wwhite on PROD1PC65 with NOTICES BILLING CODE 4410–09–P Manufacturer of Controlled Substances; Notice of Application Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 23, 2005, Noramco Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: Drug Schedule Codeine-N-Oxide (9053) .............. Morphine-N-Oxide (9307) ............. Amphetamine (1100) .................... Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Morphine (9300) ........................... Thebaine (9333) ........................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ 16:59 Apr 24, 2006 Jkt 208001 I I II II II II II II II II II II The company plans to manufacture small quantities of the Schedule I controlled substances for internal testing; the Schedule II controlled substances will be manufactured in bulk for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than June 26, 2006. Dated: April 18, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–6117 Filed 4–24–06; 8:45 am] BILLING CODE 4410–09–P VerDate Aug<31>2005 NATIONAL AERONAUTICS AND SPACE ADMINISTRATION PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 [Notice: (06–027)] Notice of Information Collection Under OMB Review National Aeronautics and Space Administration (NASA). ACTION: Notice of information collection under OMB review. AGENCY: SUMMARY: The National Aeronautics and Space Administration, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995 (Pub. L. 04–13, 44 U.S.C. 3506(c)(2)(A)). All comments should be submitted within 30 calendar days from the date of this publication. ADDRESSES: All comments should be addressed to Desk Officer for NASA, Office of Information and Regulatory Affairs, Room 10236, New Executive Office Building, Washington, DC 20503. FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection instrument(s) and instructions should be directed to Mr. Walter Kit, NASA Reports Officer, NASA Headquarters, 300 E Street, SW., JE0000, Washington, DC 20546, (202) 358–1350, Walter.Kit1@nasa.gov. DATES: SUPPLEMENTARY INFORMATION: I. Abstract The National Aeronautics and Space Administration (NASA) is requesting approval for a new collection that will be used to voluntary collect ideas from the general public about ways to fulfill NASA’s technology development challenges. II. Method of Collection NASA will utilize electronic methods to collect this information, via an online Web based form. III. Data Title: NASA Centennial Challenges Idea Submission Web Forms. OMB Number: 2700–0119. Type of Review: Extension of currently approved collection. Affected Public: Individuals or households. Estimated Number of Respondents: 300. Estimated Time per Response: .25 hours. E:\FR\FM\25APN1.SGM 25APN1

Agencies

[Federal Register Volume 71, Number 79 (Tuesday, April 25, 2006)]
[Notices]
[Page 23950]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-6117]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on August 23, 2005, Noramco 
Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as a bulk manufacturer of the basic classes of controlled substances 
listed in Schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Codeine-N-Oxide (9053).....................  I
Morphine-N-Oxide (9307)....................   I
Amphetamine (1100).........................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the Schedule I 
controlled substances for internal testing; the Schedule II controlled 
substances will be manufactured in bulk for distribution to its 
customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
may be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative, Liaison and Policy Section (ODL); or any being sent via 
express mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, 
Virginia 22301; and must be filed no later than June 26, 2006.

    Dated: April 18, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E6-6117 Filed 4-24-06; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.